Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253848 | 0.90 | RXFP1 (0.77) | RXFP1SIGMAR1L3MBTL1TSHRHRH4 | |
| SCHEMBL32667651 | 0.85 | RXFP1 (0.64) | RXFP1SIGMAR1TSHRRECQLHRH4 | |
| SCHEMBL22192837 | 0.85 | RXFP1 (0.64) | RXFP1SIGMAR1TSHRRECQLHRH4 | |
| SCHEMBL30417397 | 0.84 | RXFP1 (0.68) | RXFP1SIGMAR1TSHRHRH4HRH3 | |
| SCHEMBL16026597 | 0.84 | RXFP1 (0.68) | RXFP1SIGMAR1L3MBTL1TSHRHRH4 | |
| SCHEMBL12522808 | 0.84 | RXFP1 (0.68) | RXFP1SIGMAR1TSHRHRH4HRH3 | |
| SCHEMBL16298360 | 0.83 | POLB (0.56) | RXFP1SIGMAR1L3MBTL1POLBKDM4E | |
| SCHEMBL5180736 | 0.82 | HTT (0.70) | RXFP1SIGMAR1HRH4ALDH1A1KMT2A | |
| SCHEMBL6673835 | 0.82 | RXFP1 (1.00) | RXFP1SIGMAR1POLBKDM4EHSP90AA1 | |
| SCHEMBL4468180 | 0.82 | RXFP1 (0.66) | RXFP1SIGMAR1L3MBTL1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2006136857-A1 | DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | RXFP1 3826/4885SIGMAR1 4501/4885L3MBTL1 903/4885 |
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | MRM1, ME2, SDHA | RXFP1 3218/4885SIGMAR1 3625/4885L3MBTL1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.